Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

API REF. PRICE (USD/KG)

$ 0

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Regulatory FDF Prices

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

API

FDF

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Astx-029, Compound 15 [pmid: 34387469], Compound 15 (pmid: 34387469), 2h-isoindole-2-acetamide, 6-(5-chloro-2-((tetrahydro-2h-pyran-4-yl)amino)-4-pyrimidinyl)-n-((1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)-1,3-dihydro-alpha-methyl-1-oxo-, (alphar)-, 2h-isoindole-2-acetamide, 6-[5-chloro-2-[(tetrahydro-2h-pyran-4-yl)amino]-4-pyrimidinyl]-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]-1,3-dihydro-alpha-methyl-1-oxo-, (alphar)-, Erk inhibitor astx029

Molecular Formula

C₂₉H₃₁ClFN₅O₅

Molecular Weight

584.0 g/mol

InChI Key

BVRGQPJKSKKGIH-PUAOIOHZSA-N

FDA UNII

14FDK6ISC9

Beroterkib Anhydrous is the anhydrous form of beroterkib, an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, beroterkib specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.

1 2D Structure

Beroterkib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2R)-2-[5-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxo-1H-isoindol-2-yl]-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide

2.1.2 InChI

InChI=1S/C29H31ClFN5O5/c1-16(27(38)34-25(15-37)19-9-20(31)12-22(10-19)40-2)36-14-18-4-3-17(11-23(18)28(36)39)26-24(30)13-32-29(35-26)33-21-5-7-41-8-6-21/h3-4,9-13,16,21,25,37H,5-8,14-15H2,1-2H3,(H,34,38)(H,32,33,35)/t16-,25-/m1/s1

2.1.3 InChI Key

BVRGQPJKSKKGIH-PUAOIOHZSA-N

2.2 Other Identifiers

2.2.1 UNII

14FDK6ISC9

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-(6-(5-chloro-2-((oxan-4-yl)amino)pyrimidin-4-yl)-1-oxo-2,3-dihydro-1h-isoindol-2-yl)-n-(1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)propanamide

2.3.2 Depositor-Supplied Synonyms

1. Astx-029

2. Compound 15 [pmid: 34387469]

3. Compound 15 (pmid: 34387469)

4. 2h-isoindole-2-acetamide, 6-(5-chloro-2-((tetrahydro-2h-pyran-4-yl)amino)-4-pyrimidinyl)-n-((1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)-1,3-dihydro-alpha-methyl-1-oxo-, (alphar)-

5. 2h-isoindole-2-acetamide, 6-[5-chloro-2-[(tetrahydro-2h-pyran-4-yl)amino]-4-pyrimidinyl]-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]-1,3-dihydro-alpha-methyl-1-oxo-, (alphar)-

6. Erk Inhibitor Astx029

7. Erk 1/2 Inhibitor Astx029

8. Extracellular Signal-regulated Kinase Inhibitor Astx029

9. Extracellular Signal-regulated Kinase 1/2 Inhibitor Astx029

10. 2-(6-(5-chloro-2-((oxan-4-yl)amino)pyrimidin-4-yl)-1-oxo-2,3-dihydro-1h-isoindol-2-yl)-n-(1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)propanamide

11. 2h-isoindole-2-acetamide, 6-(5-chloro-2-((tetrahydro-2h-pyran-4-yl)amino)-4-pyrimidinyl)-n-((1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)-1,3-dihydro-.alpha.-methyl-1-oxo-, (.alpha.r)-

12. 2095719-92-7

13. Erk1/2 Inhibitor 2

14. (alphar)-6-[5-chloro-2-[(tetrahydro-2h-pyran-4-yl)amino]-4-pyrimidinyl]-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]-1,3-dihydro-alpha-methyl-1-oxo-2h-isoindole-2-acetamide

15. 14fdk6isc9

16. (2r)-2-[5-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxo-1h-isoindol-2-yl]-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide

17. Beroterkib

18. (r)-2-(6-(5-chloro-2-((tetrahydro-2h-pyran-4-yl)amino)pyrimidin-4-yl)-1-oxoisoindolin-2-yl)-n-((s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)propanamide

19. (2~{r})-2-[5-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxidanylidene-1~{h}-isoindol-2-yl]-~{n}-[(1~{s})-1-(3-fluoranyl-5-methoxy-phenyl)-2-oxidanyl-ethyl]propanamide

20. Beroterkib [inn]

21. Beroterkib Anhydrous

22. Unii-14fdk6isc9

23. Chembl4847260

24. Schembl18765557

25. Gtpl11727

26. Bdbm418007

27. Ex-a4375

28. Nsc836440

29. Us10457669, Example 685

30. Akos040759413

31. Erk1/2 Inhibitor 2(astx-029)?

32. Nsc-836440

33. Us10457669, Example 1083

34. Ac-36904

35. At-35029

36. Ts-09810

37. Hy-126288

38. Cs-0101412

39. G17546

40. (

41. Ar)-6-[5-chloro-2-[(tetrahydro-2h-pyran-4-yl)amino]-4-pyrimidinyl]-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]-1,3-dihydro-

42. A-methyl-1-oxo-2h-isoindole-2-acetamide

43. (2r)-2-(6-(5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl)-1-oxo-2,3-dihydro-1h-isoindol-2-yl)-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide

44. (2r)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1,3-dihydro-2h-1-oxoisoindol-2-yl)-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide

45. (2r)-2-{6-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-1-oxo-3h-isoindol-2-yl}-n-[(1s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide

46. (r)-2-(6-{5-chloro-2-[(tetrahydro-2h-pyran-4-yl)amino]pyrimidin-4-yl}-1-oxoisoindolin-2-yl)-n-[(s)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propenamide

47. Ryw

2.4 Create Date

2017-08-04

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₃₁ClFN₅O₅
Molecular Weight	584.0 g/mol
XLogP3	2.9
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	9
Exact Mass	Da
Monoisotopic Mass	Da
Topological Polar Surface Area	126
Heavy Atom Count	41
Formal Charge	0
Complexity	900
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1